Clinical development costs are rising due to the disruption of shipping routes in the Strait of Hormuz, writes Mathini ...

Novo Nordisks Aleksandar Ciric writes that leaders can apply sports principles such as speed of action, clarity, and ...

Speed to market wont guarantee success in todays launch environment. Anticipating what prescribers, patients and payers will ...

Biotech is the most honest leadership environment in the world. Science does not soften bad news. Markets do not wait for leaders to feel ready. And the pressure does not lift between a failed trial, ...

In the pharmaceutical industry, where innovation cycles span decades and billions of dollars hinge on patent protection, the relationship between a company and its external intellectual property ...

Empirical research comparing corporate and academic spin-offs consistently shows that corporate-originated ventures outperform their academic counterparts in terms of growth and survival. This ...

Marc Tessier-Lavigne, Ph.D. (left) and Martin Makary, M.D. (right) The FDA must “cut the idle time” that exists within the agency to bring drugs to market faster, said Commissioner Martin Makary, M.D.

Royalty-bearing license agreements are a cornerstone of commercialization in the life sciences and technology industries. Companies often use them to expand their business into new markets while ...

Over the years, I’ve had the privilege of working alongside some extraordinary leaders. When I reflect on those who have left the most lasting impact on me, I often describe them as having what I call ...

Policy pressure, affordability gaps, and consumer expectations are reshaping how pharma companies think about direct to patient access. The question is no longer if, but how. Pharmaceutical companies ...

As the life sciences industry grapples with the demands of AI and the need to integrate real-world evidence into increasingly complex pipelines, the FAIR data principles — Findable, Accessible, ...